title: Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.
abstract: Chromosomal beta-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against beta-lactams. Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal beta-lactamase (a beta ab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum a beta ab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study. The a beta ab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P < 0.0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The a beta ab levels correlated (r = 0.51, P = 0.0001) with the number of beta-lactam courses. A 14 fold increase in a beta ab levels occurred during the 14 year period covered by the longitudinal study. The results of this study show that a beta ab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to beta-lactams.
authors.affiliation: Institute of Medical Microbiology and Immunology, University of Copenhagen, Denmark.
authors.forename: O
authors.initials: O
authors.lastname: Ciofu
authors.forename: B
authors.initials: B
authors.lastname: Giwercman
authors.forename: J
authors.initials: J
authors.lastname: Walter-Rasmussen
authors.forename: T
authors.initials: T
authors.lastname: Pressler
authors.forename: S S
authors.initials: SS
authors.lastname: Pedersen
authors.forename: N
authors.initials: N
authors.lastname: Høiby
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis*; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D002876:Chromosomes, Bacterial / Q000201:enzymology*; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000276:immunology* / Q000382:microbiology; D004352:Drug Resistance, Microbial; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000276:immunology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D001618:beta-Lactamases / Q000276:immunology*; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000907:Antibodies, Bacterial; D015415:Biomarkers; D047090:beta-Lactams; D001618:beta-Lactamases